TREATMENT PATTERNS AND HEALTH CARE COSTS IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)TREATMENT PATTERNS AND HEALTH CARE COSTS IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)

被引：0
|
作者：
Clancy, Z. [1 ]
Bell, E. [2 ]
Chastek, B. [3 ]
Bunner, S. [3 ]
Copher, R. [1 ]
Arekapudi, S. [4 ]
机构：
[1] Bristol Myers Squibb, Summit, NJ USA
[2] Optum, Minneapolis, MN USA
[3] Optum, Eden Prairie, MN USA
[4] Univ Calif San Francisco, Fresno, CA USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN104
引用
收藏
页码：S41 / S41
页数：1
相关论文
共 50 条
  • [1] TREATMENT PATTERNS AND HEALTH CARE COSTS IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
    Clancy, Z.
    Bell, E.
    Chastek, B.
    Bunner, S.
    Copher, R.
    Arekapudi, S.
    VALUE IN HEALTH, 2020, 23 : S43 - S43
  • [2] Mosunetuzumab with Lenalidomide Augmentation As First-Line Therapy for Follicular (FL) and Marginal Zone Lymphoma (MZL)
    Olszewski, Adam J.
    Huntington, Scott F.
    Bannerji, Rajat
    Ollila, Thomas A.
    McMahon, Jessica
    Dubielecka, Patrycja M.
    BLOOD, 2022, 140 : 6492 - 6493
  • [3] Clinic and treatment of different variants of lymphoma of the marginal zone (MZL)
    Lepkov, S.
    Subortceva, I.
    Zeynalova, P.
    Tumyn, G.
    Semenova, A.
    Kokosadze, N.
    Kuprishina, N.
    Kolomiytsev, O.
    Borisovsckay, S.
    Rybuhina, J.
    Kovrigina, A.
    Ettinger, O.
    Zaharov, O.
    Lazarev, I.
    Nikitin, I.
    Ivashenco, R.
    Urvantceva, O.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 178 - 179
  • [4] Autoimmunity in lymphoplasmacytoid lymphoma (LPL) and marginal zone lymphoma (MZL)
    Ferrari, S.
    Tucci, A.
    Rinaldi, M.
    Ambrosetti, A.
    Rossi, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 228 - 229
  • [5] Real-world treatment (tx) patterns and economic burden of patients (pts) with marginal zone lymphoma (MZL).
    Yang, Keri
    Liu, Tom
    Tang, Boxiong
    Shah, Bijal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18730 - E18730
  • [6] A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL).
    Olszewski, Adam J.
    Huntington, Scott F.
    Ollila, Thomas
    Pelcovits, Ari
    McMahon, Jessica B.
    Yakirevich, Inna
    Sturtevant, Ashlee
    Chorzalska, Anna
    Morgan, John
    Dubielecka, Patrycja
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Results of upfront therapy for marginal zone lymphoma (MZL).
    Cabanillas, Fernando
    Ortega, Jose Luis
    Rivera-Rodriguez, Noridza
    Rodriguez, Blanca
    Pardo, Wandaly Ibis
    Pavia, Orestes Antonio
    Bruno, Margarita
    Santiago, Karen J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Phase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with follicular (FL) or marginal zone (MZL) lymphoma: Final results.
    De Vos, Sven
    Dakhil, Shaker R.
    McLaughlin, Peter
    Saleh, Mansoor N.
    Belt, Robert
    Flowers, Christopher
    Holladay, Charles
    Knapp, Mark
    Boral, Anthony
    Zhang, Tracy
    Goy, Andre
    BLOOD, 2006, 108 (11) : 208A - 208A
  • [9] Burden of illness of follicular lymphoma and marginal zone lymphoma
    Monga, Neerav
    Nastoupil, Loretta
    Garside, Jamie
    Quigley, Joan
    Hudson, Moira
    O'Donovan, Peter
    Parisi, Lori
    Tapprich, Christoph
    Thieblemont, Catherine
    ANNALS OF HEMATOLOGY, 2019, 98 (01) : 175 - 183
  • [10] Burden of illness of follicular lymphoma and marginal zone lymphoma
    Neerav Monga
    Loretta Nastoupil
    Jamie Garside
    Joan Quigley
    Moira Hudson
    Peter O’Donovan
    Lori Parisi
    Christoph Tapprich
    Catherine Thieblemont
    Annals of Hematology, 2019, 98 : 175 - 183
12345